CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Developmen...( - Enrollment completed in Phase I...),Health

- Enrollment completed in Phase II trial evaluating a single dose of

velafermin for the prevention of severe oral mucositis - - Continued focus to define registrational path for belinostat in the

treatment of cancer - - Conference call and webcast to be held today at 6:00 p.m. Eastern Time -

BRANFORD, Conn., Aug. 6 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced that a conference call will be hosted at 6:00 p.m. Eastern time to provide an update on its clinical pipeline. Dr. Frank Armstrong, President and Chief Executive Officer, and Dr. Timothy Shannon, Executive Vice President and Chief Medical Officer, will provide an update on the Company's clinical programs including:

Velafermin for the prevention of severe oral mucositis (OM):

Enrollment has been completed in the Phase II randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single infusion of velafermin for the prevention of severe OM. A total of 390 patients at 33 centers were enrolled throughout the United States. Primary safety and efficacy assessments of treated patients will be concluded at participating centers during August with preliminary, top-line efficacy results from the completed trial available in mid-October of 2007. Patients will be followed for an additional year to assess long term outcome with results available during the fourth quarter of 2008. The Phase II trial is designed to assess the reduction in the incidence of severe WHO Grade 3 or 4 OM in patients receiving high-dose chemotherapy, with or without total body irradiation (TBI), prior to autolo
'/>"/>

SOURCE CuraGen Corporation Copyright©2007 PR Newswire.

0 GOOD